2214-PUB: An Open-Label Study of Gemcabene in Adults with Familial Partial Lipodystrophy
Sign Up to like & getrecommendations! Published in 2020 at "Diabetes"
DOI: 10.2337/db20-2214-pub
Abstract: Familial Partial Lipodystrophy (FPLD) is characterized by partial loss of subcutaneous fat accompanied by metabolic abnormalities, not responding well to conventionally available therapies. Gemcabene calcium is a monocalcium salt of a dialkyl ether dicarboxylic acid… read more here.
Keywords: gemphire therapeutics; study; self; therapeutics inc ... See more keywords